Healthcare Investing
Beyond the Holiday Joke: The Trillion-Dollar Economic Shift Fueled by GLP-1 Drugs
A satirical FT comment reveals a profound truth: weight-loss drugs are not just a health trend, but a seismic economic force reshaping global markets.
The Great Pharma Migration: Why Europe is Losing Billions in Investment to the US
Europe’s pharma industry faces a crisis as US incentives like the IRA lure away billions in investment, threatening the continent’s economic future.
Medline’s Blockbuster $6 Billion IPO: The Bellwether for a New Bull Market?
Medline’s blockbuster $6B+ IPO, the largest of 2025, signals a major return of investor confidence and a potential turning point for the stock market.
Beyond the Picket Line: A Financial Analysis of the UK Doctors’ Strike and Its Economic Shockwaves
A financial analysis of the UK junior doctors’ strike, exploring its deep economic impact on public finance, the stock market, and investor sentiment.
The Hundred-Billion-Dollar Pill: Inside Pfizer’s High-Stakes Gamble to Conquer the Weight-Loss Market
Pfizer is betting billions on an oral weight-loss pill to challenge Novo Nordisk and Eli Lilly’s injectable dominance in a market poised to hit $100B.
The Trillion-Dollar Blind Spot: Why Private Equity is Making a Big Bet on Women’s Health
Private equity’s profit-driven playbook meets the underserved women’s health market, creating a trillion-dollar opportunity for innovation and disruption.
The Investor’s Paradox: What a “Thrifty Gene” Reveals About Surviving a Bull Market
A biological paradox about a ‘thrifty gene’ offers a powerful lesson for investors on rethinking risk, corporate strategy, and economic health.
The $100 Trillion Silent Pandemic: A Financial Blueprint to Avert Global Economic Collapse
Antimicrobial resistance (AMR) is a $100 trillion threat to the global economy. This article explores a financial blueprint to fix the broken antibiotic market.